Données probantes et valeur ajoutée: Évaluation des nouvelles technologies de la santé pour le traitement de l'infarctus du myocarde avec élévation du segment ST (IAMEST)


Brian James Potter

Centre hospitalier de l'Université de Montréal [CHUM]


Domaine : service de santé

Programme Chercheurs-boursiers cliniciens - Junior 1

Concours 2019-2020

Cardiology interventions are among the costliest in medicine and new ones are being developed all the time. Because healthcare resources are not unlimited, it is not possible to pay for all available treatments. Healthcare policy-makers (the Ministry of Health and Social Services) must routinely re-evaluate which treatments provide the greatest value to the population for the cost in order to decide which are essential and which may not be worthwhile. The best time to do this is typically just before the medical community begins to use new treatments more broadly. Health technology assessment (HTA) represents a constellation of methods designed to ensure the fair assessment different interventions for a given condition and can help policy makers make the right choices in terms of what therapies to make available to patients and their doctors.

This research program is designed to evaluate three treatment strategies for patients suffering a heart attack that are in this early period: (1) computerized heart attack identification (using a machine instead of a doctor) before the patient arrives at the hospital; (2) a new combination therapy to open the blocked arteries of heart attack victims (called a pharmacoinvasive strategy); and (3) supporting the sickest patients (in cardiogenic shock) with an artificial heart pump. These three treatment strategies are important to study because their cost is high and the impact on patient well-being for these conditions is potentially great. They have also been identified by the Ministry of Health as priority areas for health technology assessment.